Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Phase 3 clinical study results of bazedoxifene released

Wyeth Pharmaceuticals, a division of Wyeth, announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis.

15 Sep 2009

Halozyme Therapeutics to present its product development pipeline

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the UBS Global Life Sciences Conference to be held on September 21-23, 2009 in New York City.

15 Sep 2009

Elekta announces interim results

Demand for Elekta’s clinical solutions, products and services remained strong in the first three months of 2009/10. Order bookings rose by 19 percent in local currency with solid performance in all regions. Net sales grew to SEK 1,440 M and operating result rose to SEK 89 M. Earnings per share improved to SEK 0.62 from SEK 0.02.

From Elekta 15 Sep 2009

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT), the world’s leading developer of medical devices, announced today the presentation of new pre-clinical research findings from their Huntington’s disease program at the 2009 World Congress on Huntington’s Disease held September 12-15, 2009 in Vancouver, British Columbia.

15 Sep 2009

NCF aims to improve cancer care by providing easily accessible tools

The NavigateCancer Foundation (NCF), a nonprofit staffed by oncology professionals, provides patient advocacy tools and services for cancer patients and families, is filling an especially vital role as the ranks of the unemployed and uninsured steadily swell.

15 Sep 2009

Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced presentation of data from an interim analysis of CLI-107-06 (INSPIRE), a Phase I/IIa study of HIV-infected patients with low CD4 T cell counts. The patients were treated with a three-injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107).

15 Sep 2009

Genova gains access to Big Pharma's distribution channels

GENova Biotherapeutics Inc. ("GENova"), a cancer drug acquisition and development company, is pleased to announce it has gained access to distribution channels for its promising drug targets through a recently-signed deal with Bridge BioResearch Plc. ("Bridge BioResearch").

15 Sep 2009

Targeted Molecular Diagnostics to offer digital pathology services in Beijing

Targeted Molecular Diagnostics (TMD), a Quintiles Central Laboratory, announced today the availability of digital pathology services in Beijing, China. The services add to Quintiles offerings used in the development of therapies to treat the world’s most pressing health issues, including cancer.

15 Sep 2009

Pieris AG and Allergan sign collaboration agreement

Pieris AG today announced that they have entered into a collaboration agreement with Allergan, Inc. (NYSE: AGN) that combines Pieris' proprietary Anticalin technology with Allergan's expertise in drug delivery and ophthalmic drug development with a goal of developing agents for the treatment of serious ocular disorders.

15 Sep 2009

Antibiotics sold online without prescriptions, according to MUSC researchers

According to MUSC researchers, antibiotics are widely available for purchase on the Internet without a prescription, despite efforts to control antibiotic-resistant bacteria as a result of misuse of these drugs.

15 Sep 2009

Stem cell therapy holds great promise for regenerative medicine

The recipients of The 2009 Lasker Awards, announced today, represent the dramatic advances achieved in biotechnology research that have led to a revolutionary cancer treatment and the tremendous promise of stem cell therapy for regenerative medicine. Such advances portend a potential $700 million global market for new therapies within less than five years, according to Genetic Engineering & Biotechnology News (GEN, www.genengnews.com).

15 Sep 2009

New operating model for speed delivery of innovative medicines

Eli Lilly and Company (NYSE: LLY) today unveiled a new operating model and announced a series of changes to speed medicines from its pipeline to patients.

15 Sep 2009

miR-200 supression shifts primary lung cancer to metastatic disease

Primary lung cancer shifts to metastatic disease by suppressing a family of small molecules that normally locks the tumor in a noninvasive state, researchers at The University of Texas M. D. Anderson Cancer Center report in the Sept. 15 edition of Genes and Development.

15 Sep 2009

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.

15 Sep 2009

Loyola University receives funds to renovate bone marrow transplant unit

Loyola University Medical Center has received a $2 million matching grant from The Coleman Foundation to renovate the hospital's nationally known bone marrow transplant unit. Intended to encourage private donations for the project, the grant will match gifts up to $2 million on a dollar for dollar basis, through August 2010.

15 Sep 2009

GENova Biotherapeutics and Bridge Bioresearch sign collaboration agreement

GENova Biotherapeutics Inc. ("GENova") today announced it has signed a collaboration agreement with Bridge Bioresearch Plc. ("Bridge Bioresearch"), an international drug development and discovery company that focuses on metabolic disorders.

15 Sep 2009

Third-quarter fiscal 2009 results announced by DiagnoCure

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced revenue of $396,468 and a net loss of $4,034,364 or $0.09 per share for the third quarter ending July 31, 2009.

15 Sep 2009

UCLA receives funds for oral cancer research training

The UCLA School of Dentistry consistently ranks among the country's top dental schools in National Institutes of Health funding. During the past three fiscal years, the school has secured nearly $30 million in grants for oral cancer research and research training. Now, the dental school has received a major infusion of construction funding for the creation of the UCLA Yip Center for Oral/Head & Neck Oncology Research.

15 Sep 2009

BioAlliance announces Phase III results of miconazole Lauriad MBT for treatment of oropharyngeal candidiasis

Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that its development partner BioAlliance Pharma SA presented Phase III study results for miconazole Lauriad(R) mucoadhesive buccal tablets (MBT) that demonstrate noninferiority to clotrimazole troches for oropharyngeal candidiasis (OPC), an opportunistic infection of the mouth and throat.

14 Sep 2009

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.

14 Sep 2009